NCT04805801View on ClinicalTrials.gov

The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors

UnknownOBSERVATIONAL
Enrollment

17

Participants

Timeline

Start Date

August 28, 2019

Primary Completion Date

July 31, 2024

Study Completion Date

February 28, 2025

Conditions
Hemophilia A With InhibitorHemophilia A Without Inhibitor
Interventions
DRUG

Emicizumab subcutaneous injection

Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.

Trial Locations (1)

Unknown

RECRUITING

Yonsei University Severance Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical
All Listed Sponsors
lead

JW Pharmaceutical

INDUSTRY

NCT04805801 - The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors | Biotech Hunter | Biotech Hunter